Vaccines
for the Future

Our proprietary 1c-SApNP® Vaccine platform employs stable, multi-layered protein nanoparticles t deliver rationally designed antigens to elicit protective immune responses against infectious diseases that threaten global health.

Our Vision

To become a global leader in the vaccine industry and offer vaccine solutions for unmet public health needs

Our Mission

Working to solve the world's infectious disease threats by combining rational antigen design and protein engineering to create virus-like particle vaccines

Key Milestones
  • 2018

    Uvax Bio was founded, utilizing proprietary 1c-SApNP® platform technology developed by Dr. Jiang Zhu.

  • 2020

    1c-SApNP® vaccine construct design was finalized for HIV-1.  High-yield research cell bank (RCB) development started.

  • 2022

    HIV-1 vaccine candidates in preparation for Phase 1 trials. Three new vaccine assets currently in RCB development.

  • 2023

    HIV-1 Preclinical data published. The National Institutes of Health (NIH) has agreed to sponsor a Phase 1 clinical trial.